PDE-5 inhibitors: current status and future trends. Review uri icon

Overview

abstract

  • Phosphodiesterase-5 (PDE-5) inhibitors are a well-established, first-line therapy for erectile dysfunction (ED). Extensive clinical trials and clinical experience established the highly significant efficacy and the safety of this class of drugs in the treatment of ED.Furthermore, the efficacy of PDE-5 inhibitors has been established in men with ED with a broad range of etiologies and comorbidities. The future of PDE-5 inhibitors includes the expansion of indications such as the treatment of pulmonary hypertension and the potential of treatment of symptomatic BPH.

publication date

  • November 1, 2005

Research

keywords

  • Carbolines
  • Erectile Dysfunction
  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Phosphoric Diester Hydrolases
  • Piperazines

Identity

Scopus Document Identifier

  • 27744447233

Digital Object Identifier (DOI)

  • 10.1016/j.ucl.2005.08.012

PubMed ID

  • 16291042

Additional Document Info

volume

  • 32

issue

  • 4